Cyclacel to Report New Sapacitabine Clinical Data at the American Society of ... 
MarketWatch (press release)
Sapacitabine (CYC682), an orally-available nucleoside analogue, is in the SEAMLESS, registration-directed, Phase 3 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML), Phase 2 trials in patients with hematological malignancies, ...

and more » 

Life, Interrupted: Hope Is My New Address 
New York Times (blog)
I had for a month been living in isolation in the bone marrow transplant unit of Memorial Sloan-Kettering Cancer Center, my only option after my diagnosis with acute myeloid leukemia last year. Now, the doctors cautioned me that while my immune system ...

 

Benefit planned June 23 for the late Lovie Smith 
Weekly Citizen
By Staff reports Lovie Smith was diagnosed in September of 2011 with Acute Myeloid Leukemia. After a 6 month hospital stay and aggressive chemo treatments, she lost her tough battle on Feb. 28, 2012. To help the family cover the cost of medical bills, ...

 

'Life, Interrupted' By Cancer Diagnosis At 22 
WBUR
(Seamus McKiernan / ) Just months after moving to Paris to start her first full-time job, Suleika Jaouad was diagnosed with cancer ? acute myeloid leukemia. Like many who face life-threatening illnesses in their twenties, she is coping with a ...

and more » 

A microRNA Prognostic Marker Identified in Acute Leukemia 
Science Daily (press release)
ScienceDaily (May 14, 2012) ? A study has identified microRNA-3151 as a new independent prognostic marker in certain patients with acute leukemia. The study involves patients with acute myeloid leukemia and normal-looking chromosomes(CN-AML).

and more » 

Sunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and ... 
MarketWatch (press release)
In April, the European Commission granted orphan drug designation to vosaroxin for the treatment of acute myeloid leukemia (AML). The designation provides for 10 years of marketing exclusivity subsequent to product approval in Europe.

and more » 

Sunesis Pharmaceuticals Receives European Orphan Drug Designation for ... 
MarketWatch (press release)
... via COMTEX) -- Sunesis Pharmaceuticals, Inc. (UTD:SNSS) today announced that the European Commission has granted orphan drug designation to vosaroxin, the Company's lead development candidate, for the treatment of acute myeloid leukemia (AML).

and more » 

Call for New Treatment Approaches in Acute Myeloid Leukemia 
Cancer Network
By Anna Azvolinsky, PhD | April 27, 2012 Two researchers from the Mayo Clinic in Rochester, Minnesota, have published an editorial in the Journal of Clinical Oncology on new regimens for acute myeloid leukemia (AML) in which they argue that "radical ...

 

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2 ... 
MarketWatch (press release)
Sapacitabine (CYC682), an orally-available nucleoside analogue, is currently being evaluated in SEAMLESS, a registration-directed, Phase 3 trial in elderly patients with newly diagnosed acute myeloid leukemia (AML), Phase 2 trials in patients with ...
Cyclacel Reports First Quarter 2012 Financial Results Broadcast Newsroom

all 11 news articles » 

New island tradition starts Saturday 
Jamestown Press
The charity was created in memory of Payton Watson, a North Kingstown youngster who was diagnosed with acute myelogenous leukemia in October 2006. Her parents heard the bad news after Payton suffered from strep throat that would not go away.